These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35986867)

  • 61. Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey.
    Larsen TB; Potpara T; Dagres N; Proclemer A; Sciarrafia E; Blomström-Lundqvist C;
    Europace; 2015 May; 17(5):819-24. PubMed ID: 25926476
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Concurrent use of P-glycoprotein or Cytochrome 3A4 drugs and non-vitamin K antagonist oral anticoagulants in non-valvular atrial fibrillation.
    Sandhu RK; Islam S; Dover DC; Andrade JG; Ezekowitz J; McAlister FA; Hawkins NM; Kaul P
    Eur Heart J Qual Care Clin Outcomes; 2022 Mar; 8(2):195-201. PubMed ID: 33480405
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A retrospective study on the evaluation of the appropriateness of oral anticoagulant therapy for patients with atrial fibrillation.
    Qian Y; Zhang J; Li J; Weng Z
    PLoS One; 2021; 16(11):e0259199. PubMed ID: 34762667
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Stroke and bleeding risk scores in patients with atrial fibrillation and valvular heart disease: evaluating 'valvular heart disease' in a nationwide cohort study.
    Lip GYH; Jensen M; Melgaard L; Skjøth F; Nielsen PB; Larsen TB
    Europace; 2019 Jan; 21(1):33-40. PubMed ID: 29986001
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation.
    Steinberg BA; Washam JB
    Trends Cardiovasc Med; 2017 Nov; 27(8):567-572. PubMed ID: 28750830
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation.
    Li RJ; Caughey GE; Shakib S
    J Thromb Thrombolysis; 2022 Feb; 53(2):425-435. PubMed ID: 34302286
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and hypertrophic cardiomyopathy].
    Liu YY; Du X; He L; Hu R; Ning M; Lyu J; Dong JZ; Ma CS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Jan; 50(1):62-67. PubMed ID: 35045616
    [No Abstract]   [Full Text] [Related]  

  • 68. Assessing major bleeding risk in atrial fibrillation patients concurrently taking non-vitamin K antagonist oral anticoagulants and antiepileptic drugs.
    Wang CL; Wu VC; Chang KH; Tu HT; Kuo CF; Huang YT; Chu PH; Kuo CC; Chang SH
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(3):147-154. PubMed ID: 31384926
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment.
    Turpie AGG; Purdham D; Ciaccia A
    Ther Adv Cardiovasc Dis; 2017 Sep; 11(9):243-256. PubMed ID: 28651452
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants.
    Hankey GJ
    Thromb Haemost; 2014 May; 111(5):808-16. PubMed ID: 24285341
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Community pharmacy-based study of adherence to non-vitamin K antagonist oral anticoagulants.
    Capiau A; Mehuys E; Van Tongelen I; Christiaens T; De Sutter A; Steurbaut S; Moudallel S; Rydant S; Vrijens B; de Backer TLM; Boussery K
    Heart; 2020 Nov; 106(22):1740-1746. PubMed ID: 32576607
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Variability in Non-Vitamin K Antagonist Oral Anticoagulants Dose Adjustment in Atrial Fibrillation Patients With Renal Dysfunction: The Influence of Renal Function Estimation Formulae.
    Andrade JG; Hawkins NM; Fordyce CB; Deyell MW; Er L; Djurdjev O; Macle L; Virani SA; Levin A
    Can J Cardiol; 2018 Aug; 34(8):1010-1018. PubMed ID: 29980468
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials.
    Kumar S; Danik SB; Altman RK; Barrett CD; Lip GY; Chatterjee S; Roubin GS; Natale A; Danik JS
    Cardiol Rev; 2016; 24(5):218-23. PubMed ID: 26274538
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.
    Haas S; Camm AJ; Bassand JP; Angchaisuksiri P; Cools F; Corbalan R; Gibbs H; Jacobson B; Koretsune Y; Mantovani LG; Misselwitz F; Panchenko E; Ragy HI; Stepinska J; Turpie AG; Sawhney JP; Steffel J; Lim TW; Pieper KS; Virdone S; Verheugt FW; Kakkar AK;
    Am Heart J; 2019 Jul; 213():35-46. PubMed ID: 31128503
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety and efficacy of non-vitamin K antagonist oral anticoagulants in elderly patients with atrial fibrillation: systematic review and meta-analysis of 22 studies and 440 281 patients.
    Silverio A; Di Maio M; Prota C; De Angelis E; Radano I; Citro R; Carrizzo A; Ciccarelli M; Vecchione C; Capodanno D; Galasso G
    Eur Heart J Cardiovasc Pharmacother; 2021 Apr; 7(FI1):f20-f29. PubMed ID: 31830264
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation and valvular heart disease.
    Li HJ; Lin SY; Lin FJ; Hung CS; Wang CC
    Curr Med Res Opin; 2021 Apr; 37(4):535-542. PubMed ID: 33538623
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Non-Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GYH; Larsen TB
    Stroke; 2019 Apr; 50(4):939-946. PubMed ID: 30869568
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis.
    Nielsen PB; Lane DA; Rasmussen LH; Lip GY; Larsen TB
    Clin Res Cardiol; 2015 May; 104(5):418-29. PubMed ID: 25416564
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety of once- or twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with nonvalvular atrial fibrillation: A NOAC-TR study.
    Emren SV; Zoghi M; Berilgen R; Özdemir İH; Çelik O; Çetin N; Enhoş A; Köseoğlu C; Akyüz A; Doğan V; Levent F; Dereli Y; Doğan T; Başaran Ö; Karaca I; Karaca Ö; Otlu YÖ; Özmen Ç; Coşar S; Sümerkan M; Gürsul E; İnci S; Onrat E; Ergene O
    Bosn J Basic Med Sci; 2018 May; 18(2):185-190. PubMed ID: 28968197
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Real-world adherence to oral anticoagulants in atrial fibrillation].
    Simonyi G; Paksy A; Várnai R; Medvegy M
    Orv Hetil; 2020 May; 161(20):839-845. PubMed ID: 32364687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.